

Table 6.6a
Immunosuppression Use for Induction, 2000 to 2009
Recipients with Pancreas Transplant Alone (PTA) Transplants

	Year of Transplant									
	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009
Transplants	134	168	180	160	183	199	174	210	223	181
With Immunosuppression Info	128	165	176	154	179	193	168	201	219	174
Induction Drugs										
ALG	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	0.0%	0.0%	0.0%	1.3%	2.2%	0.0%	0.6%	1.0%	1.4%	1.7%
OKT3	4.7%	3.0%	3.4%	0.6%	0.0%	2.1%	5.4%	7.5%	6.4%	13.2%
Thymoglobulin	48.4%	49.1%	60.8%	45.5%	50.3%	48.2%	41.7%	41.3%	49.8%	59.2%
Zenapax	44.5%	34.5%	31.3%	8.4%	9.5%	5.2%	10.7%	7.0%	6.8%	2.9%
Simulect	9.4%	3.0%	4.0%	6.5%	0.0%	2.1%	2.4%	3.5%	4.6%	4.0%
Campath	0.0%	0.0%	1.1%	31.2%	41.3%	33.7%	23.8%	13.9%	11.4%	12.6%
No Induction Drugs Recorded	29.7%	38.8%	29.5%	18.2%	20.1%	16.6%	21.4%	33.8%	26.9%	21.8%

Source: OPTN/SRTR Data as of October 1, 2010.

Notes:

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.